Mogengel Biotech
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Mogengel Biotech - overview
Established
2021
Location
Xiamen, Fujian, China
Primary Industry
Biotechnology
About
Established in 2021 and based in Xiamen, China, Mogengel Biotech operates as an organoid culture solutions provider that provides 3D cell culture solutions. The company covers 2000 square feet and has many awards, such as Xiamen "Double Hundred Talents" enterprise and Taicang "International Youth Entrepreneurship Competition First Prize". In July 2023, it closed strategic investment from GP Capital and Jiaxing Desi Private Equity Fund Management. The company has four technology platforms, including protein expression and purification center, laboratory animal center, organoid research center and intelligent microscopy research center.
Its products are divided into three series, which include stromal gel, organoid medium and total process reagent kit, such as standard stromal gel, low growth factor matrix gel and tumor organoid culture medium. And products can apply in PDX, angiogenesis assay and cell invasion (transwell) assay. In the future, the company will expand its R&D and production base by another 5000m², including SPF-grade animal house, GMP production plant and R&D conversion center.
Current Investors
GP Capital, Kairos Capital
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Healthcare IT
Website
www.mogengel.com
Verticals
HealthTech
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.